Corrigendum: An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in Pharmacology - 11(2020) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chuantao Ye [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
BXA |
|---|
| doi: |
10.3389/fphar.2020.00201 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ055597750 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ055597750 | ||
| 003 | DE-627 | ||
| 005 | 20230503023458.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2020.00201 |2 doi | |
| 035 | |a (DE-627)DOAJ055597750 | ||
| 035 | |a (DE-599)DOAJ96bf73377ad74ff28eebf1d54fcfc1c2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Chuantao Ye |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Corrigendum: An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 650 | 4 | |a viral nucleic acid synthesis inhibitors | |
| 650 | 4 | |a hantavirus | |
| 650 | 4 | |a FFA | |
| 650 | 4 | |a T-705 | |
| 650 | 4 | |a BXA | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Chuantao Ye |e verfasserin |4 aut | |
| 700 | 0 | |a Dan Wang |e verfasserin |4 aut | |
| 700 | 0 | |a He Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Hongwei Ma |e verfasserin |4 aut | |
| 700 | 0 | |a Yangchao Dong |e verfasserin |4 aut | |
| 700 | 0 | |a Min Yao |e verfasserin |4 aut | |
| 700 | 0 | |a Yuan Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Hui Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Liang Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Linfeng Cheng |e verfasserin |4 aut | |
| 700 | 0 | |a Zhikai Xu |e verfasserin |4 aut | |
| 700 | 0 | |a Yingfeng Lei |e verfasserin |4 aut | |
| 700 | 0 | |a Fanglin Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Wei Ye |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Pharmacology |d Frontiers Media S.A., 2010 |g 11(2020) |w (DE-627)DOAJ000099732 |x 16639812 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fphar.2020.00201 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/96bf73377ad74ff28eebf1d54fcfc1c2 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/article/10.3389/fphar.2020.00201/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1663-9812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 | ||